Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients

被引:17
作者
Sumida, Yoshio [1 ]
Yonei, Yoshikazu [3 ]
Kanemasa, Kazuyuki [1 ]
Hara, Tasuku [1 ]
Inada, Yutaka [1 ]
Sakai, Kyoko [1 ]
Imai, Shunsuke [2 ]
Hibino, Sawako [4 ]
Yamaguchi, Kanji [5 ]
Mitsuyoshi, Hironori [5 ]
Yasui, Kohichiroh [5 ]
Minami, Masahito [5 ]
Itoh, Yoshito [5 ]
Naito, Yuji [5 ]
Yoshikawa, Toshikazu [5 ]
Okanoue, Takeshi [6 ]
机构
[1] Nara City Hosp, Ctr Digest & Liver Dis, Nara 6308305, Japan
[2] Nara City Hosp, Dept Pathol, Nara 6308305, Japan
[3] Doshisha Univ, Grad Sch Life & Med Sci, Antiaging Med Res Ctr, Kyotanabe, Japan
[4] Kyoto Prefectural Univ Med, Basic Res Div, Louis Pasteur Ctr Med Res, Antiaging Med Sci, Kyoto, Japan
[5] Kyoto Prefectural Univ Med, Dept Gastroenterol & Hepatol, Kyoto, Japan
[6] Saiseikai Suita Hosp, Hepatol Ctr, Suita, Osaka, Japan
关键词
fibrosis; dehydroepiandrosterone; insulin resistance; non-alcoholic fatty liver disease; FATTY LIVER-DISEASE; METABOLIC SYNDROME; OBESE-PATIENTS; MEN; SULFATE; ASSOCIATION; WOMEN; NASH; RATS; SULFOTRANSFERASE;
D O I
10.1111/j.1872-034X.2010.00704.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: The biological basis of variability in histological progression of non-alcoholic fatty liver disease (NAFLD) remains unknown. Dehydroepiandrosterone (DHEA), the most abundant steroid hormone, has been shown to influence sensitivity to reactive oxygen species, insulin sensitivity and expression of peroxisome proliferator-activated receptor-alpha. Our aim was to determine whether more histologically advanced NAFLD is associated with low circulating levels of DHEA in Japanese patients. Methods: Serum samples were obtained in 133 Japanese patients with biopsy-proven NAFLD and in 399 sex- and age-matched healthy people undergoing health checkups. Serum levels of sulfated DHEA (DHEA-S) were measured by chemiluminescent enzyme immunoassay. Results: Serum DHEA-S levels in NAFLD patients were similar to those in the control group. Of 133 patients, 90 patients were diagnosed as non-alcoholic steatohepatitis (NASH): 73 patients had stage 0-2, and 17 had stage 3 or 4. Patients with advanced NAFLD (NASH with fibrosis stage 3 or 4) had lower plasma levels of DHEA-S than patients with mild NAFLD (simple steatosis or NASH with fibrosis stage 0-2). The area under the receiver operating characteristic curve for DHEA in separating patients with and without advanced fibrosis was 0.788. A "dose effect" of lower DHEA-S and incremental fibrosis stage was observed with a mean DHEA-S of 170.4 +/- 129.2, 137.6 +/- 110.5, 96.2 +/- 79.3, 61.2 +/- 46.3 and 30.0 +/- 32.0 mu g/dL for fibrosis stages 0, 1, 2, 3, and 4, respectively. The association between DHEA-S and severity of NAFLD persisted after adjusting for age, sex and insulin resistance. Conclusion: Low circulating DHEA-S might have a role in the development of advanced NASH.
引用
收藏
页码:901 / 910
页数:10
相关论文
共 50 条
  • [31] Circulating Levels of Pro-inflammatory Cytokines in Patients with Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Hadinia, Abolghasem
    Doustimotlagh, Amir Hossein
    Goodarzi, Hamed Reza
    Arya, Arash
    Jafarinia, Mojtaba
    IRANIAN JOURNAL OF IMMUNOLOGY, 2019, 16 (04) : 327 - 333
  • [32] Molecular determinants of insulin resistance, cell apoptosis and lipid accumulation in non-alcoholic steatohepatitis
    Piro, S.
    Spadaro, L.
    Russello, M.
    Spampinato, D.
    Oliveri, C. E.
    Vasquez, E.
    Benigno, R.
    Brancato, F.
    Purrello, F.
    Rabuazzo, A. M.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2008, 18 (08) : 545 - 552
  • [33] Combined pantethine and probucol therapy for Japanese patients with non-alcoholic steatohepatitis
    Tokushige, Katsutoshi
    Hashimoto, Etsuko
    Yatsuji, Satoru
    Taniai, Makiko
    Shiratori, Keiko
    HEPATOLOGY RESEARCH, 2007, 37 (10) : 872 - 877
  • [34] Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes
    Younossi, Zobair M.
    Tampi, Radhika P.
    Nader, Fatema
    Younossi, Issah M.
    Cable, Rebecca
    Srishord, Manirath
    Racila, Andrei
    LIVER INTERNATIONAL, 2020, 40 (02) : 308 - 318
  • [35] Camel milk ameliorates steatohepatitis, insulin resistance and lipid peroxidation in experimental non-alcoholic fatty liver disease
    Korish, Aida A.
    Arafah, Maha M.
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 13
  • [36] Camel milk ameliorates steatohepatitis, insulin resistance and lipid peroxidation in experimental non-alcoholic fatty liver disease
    Aida A Korish
    Maha M Arafah
    BMC Complementary and Alternative Medicine, 13
  • [37] Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease
    Smirne, Carlo
    Mulas, Violante
    Barbaglia, Matteo Nazzareno
    Mallela, Venkata Ramana
    Minisini, Rosalba
    Barizzone, Nadia
    Burlone, Michela Emma
    Pirisi, Mario
    Grossini, Elena
    DIAGNOSTICS, 2020, 10 (12)
  • [38] Insulin resistance and neurodegeneration: Roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis
    de la Monte, Suzanne M.
    Longato, Lisa
    Tong, Ming
    Wands, Jack R.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (10) : 1049 - 1060
  • [39] Controlled attenuation parameter-insulin resistance (CIR) score to predict non-alcoholic steatohepatitis
    Macias, Juan
    Parra-Membrives, Pablo
    Sosa-Moreno, Francisco
    Rincon, Pilar
    Martinez-Baena, Dario
    Fernandez-Fuertes, Marta
    Lorente-Herce, Jose M.
    Martinez, Rafael C.
    Jimenez-Riera, Granada
    Corma-Gomez, Anais
    Gonzalez-Serna, Alejandro
    Pineda, Juan A.
    Miguel Real, Luis
    SCIENTIFIC REPORTS, 2022, 12 (01):
  • [40] The association of laminin levels with insulin resistance and non-alcoholic hepatosteatosis
    Özgür Altun
    Yücel Arman
    Şengül Aydın Yoldemir
    Ayşe Selcen Pala
    Perihan Özkan Gümüşkaya
    Mustafa Özcan
    Mustafa Karataş
    Okan Dikker
    Tufan Tükek
    Diabetology & Metabolic Syndrome, 13